Nitrate-reducing enzymes in the nitric oxide pathway

The nitrate-reducing enzymes in the nitric oxide (NO) pathway represent a group of enzymes that facilitate a non-canonical, oxygen-independent route for NO production, complementing the classical L-arginine-NOS pathway. This pathway involves the sequential reduction of inorganic nitrate to nitrite, primarily by commensal oral bacteria such as Rothia and Neisseria, followed by the further reduction of nitrite to bioactive NO by various mammalian enzymes. Key mammalian players include xanthine oxidoreductase (XOR), mitochondrial amidoxime reducing components (mARC1 and mARC2), aldehyde oxidase, and deoxygenated heme proteins like hemoglobin and myoglobin. This system is particularly vital under hypoxic or acidic conditions where traditional NOS activity is impaired, playing a crucial role in regulating vascular tone, blood pressure, and mitochondrial efficiency. Therapeutic strategies targeting this pathway include dietary nitrate supplementation (e.g., beetroot juice) and inorganic nitrite administration to treat cardiovascular and metabolic disorders. Conversely, the pathway can be disrupted by antiseptic mouthwashes that eliminate oral bacteria or proton pump inhibitors that reduce gastric acidity required for nitrite bioactivation.

Other names

Nitrate-nitrite-nitric oxide pathwayNon-canonical nitric oxide pathwayMammalian nitrate reductasesNitrite reductasesInorganic nitrate pathway

The enzymes facilitate the sequential reduction of inorganic nitrate to nitrite and then to nitric oxide (NO). This NO then activates soluble guanylate cyclase (sGC), increasing cyclic guanosine monophosphate (cGMP) levels, which leads to smooth muscle relaxation (vasodilation), improved blood flow, and modulation of mitochondrial respiration, especially under hypoxic conditions.